Compromised activity of natural killer cells in diffuse large b-cell lymphoma is related to lymphoma-induced modification of their surface receptor expression.
Cytotoxicity
Diffuse large B-cell lymphoma
Immune evasion
Inflammatory cytokines
Natural killer cells
Journal
Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
08
11
2021
accepted:
15
08
2022
pubmed:
2
9
2022
medline:
25
2
2023
entrez:
1
9
2022
Statut:
ppublish
Résumé
While natural killer (NK) cells are essential players in detection and elimination of malignant cells, these surveillance properties can be compromised by cancer cells. Since NK cell education primarily occurs in the bone marrow and lymphoid tissue, this process might be particularly affected by their infiltration with lymphoma cells. This study aimed to explore functional properties of diffuse large B-cell lymphoma (DLBCL) patient NK cells, which could potentially promote tumour immune evasion and disease propagation.NK cells isolated from the peripheral blood (PB) of 26 DLBCL patients and 13 age-matched healthy controls (HC) were analysed. The cytotoxic CD56
Identifiants
pubmed: 36048214
doi: 10.1007/s00262-022-03284-4
pii: 10.1007/s00262-022-03284-4
doi:
Substances chimiques
Antineoplastic Agents
0
CD56 Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
707-718Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Huntington ND, Vosshenrich CA, Di Santo JP (2007) Developmental pathways that generate natural-killer-cell diversity in mice and humans. Nat Rev Immunol 7(9):703–714. https://doi.org/10.1038/nri2154
doi: 10.1038/nri2154
pubmed: 17717540
Lanier LL (2005) NK cell recognition. Annu Rev Immunol 23:225–274. https://doi.org/10.1146/annurev.immunol.23.021704.115526
doi: 10.1146/annurev.immunol.23.021704.115526
pubmed: 15771571
Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, Carson WE, Caligiuri MA (2001) Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 97(10):3146–3151. https://doi.org/10.1182/blood.v97.10.3146
doi: 10.1182/blood.v97.10.3146
pubmed: 11342442
Penack O, Gentilini C, Fischer L, Asemissen AM, Scheibenbogen C, Thiel E, Uharek L (2005) CD56dimCD16neg cells are responsible for natural cytotoxicity against tumor targets. Leukemia 19(5):835–840. https://doi.org/10.1038/sj.leu.2403704
doi: 10.1038/sj.leu.2403704
pubmed: 15744340
Chan A, Hong DL, Atzberger A, Kollnberger S, Filer AD, Buckley CD, McMichael A, Enver T, Bowness P (2007) CD56bright human NK cells differentiate into CD56dim cells: role of contact with peripheral fibroblasts. J Immunol 179(1):89–94. https://doi.org/10.4049/jimmunol.179.1.89
doi: 10.4049/jimmunol.179.1.89
pubmed: 17579025
Stabile H, Nisti P, Morrone S, Pagliara D, Bertaina A, Locatelli F, Santoni A, Gismondi A (2015) Multifunctional human CD56 low CD16 low natural killer cells are the prominent subset in bone marrow of both healthy pediatric donors and leukemic patients. Haematologica 100(4):489–498. https://doi.org/10.3324/haematol.2014.116053
doi: 10.3324/haematol.2014.116053
pubmed: 25596273
pmcid: 4380722
Waldhauer I, Steinle A (2008) NK cells and cancer immunosurveillance. Oncogene 27(45):5932–5943. https://doi.org/10.1038/onc.2008.267
doi: 10.1038/onc.2008.267
pubmed: 18836474
Harning R, Koo GC, Szalay J (1989) Regulation of the metastasis of murine ocular melanoma by natural killer cells. Invest Ophthalmol Vis Sci 30(9):1909–1915
pubmed: 2777511
Kozlowski JM, Fidler IJ, Campbell D, Xu ZL, Kaighn ME, Hart IR (1984) Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer Res 44(8):3522–3529
pubmed: 6744277
Smyth MJ (2008) NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol 20(4):631. https://doi.org/10.1093/intimm/dxn028
doi: 10.1093/intimm/dxn028
pubmed: 18334503
Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K (2000) Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet 356(9244):1795–1799. https://doi.org/10.1016/S0140-6736(00)03231-1
doi: 10.1016/S0140-6736(00)03231-1
pubmed: 11117911
Kim R, Emi M, Tanabe K (2007) Cancer immunoediting from immune surveillance to immune escape. Immunology 121(1):1–14. https://doi.org/10.1111/j.1365-2567.2007.02587.x
doi: 10.1111/j.1365-2567.2007.02587.x
pubmed: 17386080
pmcid: 2265921
Markowitz JF, Aiges HW, Cunningham-Rundles S, Kahn E, Teichberg S, Fisher SE, Daum F (1986) Cancer family syndrome: marker studies. Gastroenterology 91(3):581–589. https://doi.org/10.1016/0016-5085(86)90626-8
doi: 10.1016/0016-5085(86)90626-8
pubmed: 2942437
Warren RP, Stembridge AM, Gardner EJ (1985) Deficient immune function of peripheral blood mononuclear cells from patients with Gardner syndrome. Clin Exp Immunol 60(3):525–531
pubmed: 3160513
pmcid: 1577193
Sivori S, Pende D, Bottino C, Marcenaro E, Pessino A, Biassoni R, Moretta L, Moretta A (1999) NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells. Eur J Immunol 29(5):1656–1666
doi: 10.1002/(SICI)1521-4141(199905)29:05<1656::AID-IMMU1656>3.0.CO;2-1
pubmed: 10359120
Costello RT, Sivori S, Marcenaro E, Lafage-Pochitaloff M, Mozziconacci MJ, Reviron D, Gastaut JA, Pende D, Olive D, Moretta A (2002) Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 99(10):3661–3667. https://doi.org/10.1182/blood.v99.10.3661
doi: 10.1182/blood.v99.10.3661
pubmed: 11986221
Stringaris K, Sekine T, Khoder A, Alsuliman A, Razzaghi B, Sargeant R, Pavlu J, Brisley G, de Lavallade H, Sarvaria A, Marin D, Mielke S, Apperley JF, Shpall EJ, Barrett AJ, Rezvani K (2014) Leukemia-induced phenotypic and functional defects in natural killer cells predict failure to achieve remission in acute myeloid leukemia. Haematologica 99(5):836–847. https://doi.org/10.3324/haematol.2013.087536
doi: 10.3324/haematol.2013.087536
pubmed: 24488563
pmcid: 4008119
Weiss-Steider B, Soto-Cruz I, Martinez-Campos CA, Mendoza-Rincon JF (2011) Expression of MICA, MICB and NKG2D in human leukemic myelomonocytic and cervical cancer cells. J Exp Clin Cancer Res 30:37. https://doi.org/10.1186/1756-9966-30-37
doi: 10.1186/1756-9966-30-37
pubmed: 21477352
pmcid: 3082231
Epling-Burnette PK, Bai F, Painter JS, Rollison DE, Salih HR, Krusch M, Zou J, Ku E, Zhong B, Boulware D, Moscinski L, Wei S, Djeu JY, List AF (2007) Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors. Blood 109(11):4816–4824. https://doi.org/10.1182/blood-2006-07-035519
doi: 10.1182/blood-2006-07-035519
pubmed: 17341666
pmcid: 1885518
Sanchez-Correa B, Gayoso I, Bergua JM, Casado JG, Morgado S, Solana R, Tarazona R (2012) Decreased expression of DNAM-1 on NK cells from acute myeloid leukemia patients. Immunol Cell Biol 90(1):109–115. https://doi.org/10.1038/icb.2011.15
doi: 10.1038/icb.2011.15
pubmed: 21383766
Costello RT, Boehrer A, Sanchez C, Mercier D, Baier C, Le Treut T, Sebahoun G (2013) Differential expression of natural killer cell activating receptors in blood versus bone marrow in patients with monoclonal gammopathy. Immunology 139(3):338–341. https://doi.org/10.1111/imm.12082
doi: 10.1111/imm.12082
pubmed: 23360454
pmcid: 3701180
Danielou-Lazareth A, Henry G, Geromin D, Khaznadar Z, Briere J, Tamouza R, Cayuela JM, Thieblemont C, Toubert A, Dulphy N (2013) At diagnosis, diffuse large B-cell lymphoma patients show impaired rituximab-mediated NK-cell cytotoxicity. Eur J Immunol 43(5):1383–1388. https://doi.org/10.1002/eji.201242733
doi: 10.1002/eji.201242733
pubmed: 23400905
Plonquet A, Haioun C, Jais JP, Debard AL, Salles G, Bene MC, Feugier P, Rabian C, Casasnovas O, Labalette M, Kuhlein E, Farcet JP, Emile JF, Gisselbrecht C, Delfau-Larue MH, Groupe d’etude des lymphomes de la (2007) Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2–3 diffuse large B-cell lymphoma. Ann Oncol 18(7):1209–1215. https://doi.org/10.1093/annonc/mdm110
doi: 10.1093/annonc/mdm110
pubmed: 17496307
He L, Zhu HY, Qin SC, Li Y, Miao Y, Liang JH, Xia Y, Wang Y, Wu YJ, Wang L, Fan L, Li JY, Xu W (2016) Low natural killer (NK) cell counts in peripheral blood adversely affect clinical outcome of patients with follicular lymphoma. Blood Cancer J 6(8):e457. https://doi.org/10.1038/bcj.2016.67
doi: 10.1038/bcj.2016.67
pubmed: 27518240
pmcid: 5022180
Klanova M, Oestergaard MZ, Trneny M, Hiddemann W, Marcus R, Sehn LH, Vitolo U, Bazeos A, Goede V, Zeuner H, Knapp A, Sahin D, Spielewoy N, Bolen CR, Cardona A, Klein C, Venstrom JM, Nielsen T, Fingerle-Rowson G (2019) Prognostic impact of natural killer cell count in follicular lymphoma and diffuse large B-cell lymphoma patients treated with immunochemotherapy. Clin Cancer Res 25(15):4634–4643. https://doi.org/10.1158/1078-0432.CCR-18-3270
doi: 10.1158/1078-0432.CCR-18-3270
pubmed: 31053601
Andersson LC, Nilsson K, Gahmberg CG (1979) K562–a human erythroleukemic cell line. Int J Cancer 23(2):143–147. https://doi.org/10.1002/ijc.2910230202
doi: 10.1002/ijc.2910230202
pubmed: 367973
Alter G, Malenfant JM, Altfeld M (2004) CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 294(1–2):15–22. https://doi.org/10.1016/j.jim.2004.08.008
doi: 10.1016/j.jim.2004.08.008
pubmed: 15604012
Krzewski K, Gil-Krzewska A, Nguyen V, Peruzzi G, Coligan JE (2013) LAMP1/CD107a is required for efficient perforin delivery to lytic granules and NK-cell cytotoxicity. Blood 121(23):4672–4683. https://doi.org/10.1182/blood-2012-08-453738
doi: 10.1182/blood-2012-08-453738
pubmed: 23632890
pmcid: 3674668
Levi I, Amsalem H, Nissan A, Darash-Yahana M, Peretz T, Mandelboim O, Rachmilewitz J (2015) Characterization of tumor infiltrating natural killer cell subset. Oncotarget 6(15):13835–13843. https://doi.org/10.18632/oncotarget.3453
doi: 10.18632/oncotarget.3453
pubmed: 26079948
pmcid: 4537053
Richards JO, Chang X, Blaser BW, Caligiuri MA, Zheng P, Liu Y (2006) Tumor growth impedes natural-killer-cell maturation in the bone marrow. Blood 108(1):246–252. https://doi.org/10.1182/blood-2005-11-4535
doi: 10.1182/blood-2005-11-4535
pubmed: 16556890
pmcid: 1895835
Pierson BA, Miller JS (1996) CD56+bright and CD56+dim natural killer cells in patients with chronic myelogenous leukemia progressively decrease in number, respond less to stimuli that recruit clonogenic natural killer cells, and exhibit decreased proliferation on a per cell basis. Blood 88(6):2279–2287
doi: 10.1182/blood.V88.6.2279.bloodjournal8862279
pubmed: 8822949
Koo KC, Shim DH, Yang CM, Lee SB, Kim SM, Shin TY, Kim KH, Yoon HG, Rha KH, Lee JM, Hong SJ (2013) Reduction of the CD16(-)CD56bright NK cell subset precedes NK cell dysfunction in prostate cancer. PLoS ONE 8(11):e78049. https://doi.org/10.1371/journal.pone.0078049
doi: 10.1371/journal.pone.0078049
pubmed: 24223759
pmcid: 3817174
Wulff S, Pries R, Borngen K, Trenkle T, Wollenberg B (2009) Decreased levels of circulating regulatory NK cells in patients with head and neck cancer throughout all tumor stages. Anticancer Res 29(8):3053–3057
pubmed: 19661315
de Jonge K, Ebering A, Nassiri S, Maby-El Hajjami H, Ouertatani-Sakouhi H, Baumgaertner P, Speiser DE (2019) Circulating CD56(bright) NK cells inversely correlate with survival of melanoma patients. Sci Rep 9(1):4487. https://doi.org/10.1038/s41598-019-40933-8
doi: 10.1038/s41598-019-40933-8
pubmed: 30872676
pmcid: 6418246
Cai L, Zhang Z, Zhou L, Wang H, Fu J, Zhang S, Shi M, Zhang H, Yang Y, Wu H, Tien P, Wang FS (2008) Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clin Immunol 129(3):428–437. https://doi.org/10.1016/j.clim.2008.08.012
doi: 10.1016/j.clim.2008.08.012
pubmed: 18824414
Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trneny M, Sharman JP, Herbaux C, Burke JM, Matasar M, Rai S, Izutsu K, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W, Song Y, Greil R, Mykhalska L, Bergua-Burgues JM, Cheung MC, Pinto A, Shin HJ, Hapgood G, Munhoz E, Abrisqueta P, Gau JP, Hirata J, Jiang Y, Yan M, Lee C, Flowers CR, Salles G (2022) Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 386(4):351–363. https://doi.org/10.1056/NEJMoa2115304
doi: 10.1056/NEJMoa2115304
pubmed: 34904799
Orr MT, Lanier LL (2010) Natural killer cell education and tolerance. Cell 142(6):847–856. https://doi.org/10.1016/j.cell.2010.08.031
doi: 10.1016/j.cell.2010.08.031
pubmed: 20850008
pmcid: 2945212
Brodin P, Karre K, Hoglund P (2009) NK cell education: not an on-off switch but a tunable rheostat. Trends Immunol 30(4):143–149. https://doi.org/10.1016/j.it.2009.01.006
doi: 10.1016/j.it.2009.01.006
pubmed: 19282243
Al Omar SY, Marshall E, Middleton D, Christmas SE (2011) Increased killer immunoglobulin-like receptor expression and functional defects in natural killer cells in lung cancer. Immunology 133(1):94–104. https://doi.org/10.1111/j.1365-2567.2011.03415.x
doi: 10.1111/j.1365-2567.2011.03415.x
pubmed: 21342183
pmcid: 3088971
Barani S, Hosseini SV, Ghaderi A (2019) Activating and inhibitory killer cell immunoglobulin like receptors (KIR) genes are involved in an increased susceptibility to colorectal adenocarcinoma and protection against invasion and metastasis. Immunobiology 224(5):681–686. https://doi.org/10.1016/j.imbio.2019.06.002
doi: 10.1016/j.imbio.2019.06.002
pubmed: 31248612
Butsch Kovacic M, Martin M, Gao X, Fuksenko T, Chen CJ, Cheng YJ, Chen JY, Apple R, Hildesheim A, Carrington M (2005) Variation of the killer cell immunoglobulin-like receptors and HLA-C genes in nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev 14(11 Pt 1):2673–2677. https://doi.org/10.1158/1055-9965.EPI-05-0229
doi: 10.1158/1055-9965.EPI-05-0229
pubmed: 16284396
Muriuki BM, Forconi CS, Oluoch PO, Bailey JA, Ghansah A, Moormann AM, Ong’echa JM (2021) Association of killer cell immunoglobulin-like receptors with endemic burkitt lymphoma in Kenyan children. Sci Rep 11(1):11343. https://doi.org/10.1038/s41598-021-90596-7
doi: 10.1038/s41598-021-90596-7
pubmed: 34059753
pmcid: 8166913
Kamiya T, Seow SV, Wong D, Robinson M, Campana D (2019) Blocking expression of inhibitory receptor NKG2A overcomes tumor resistance to NK cells. J Clin Invest 129(5):2094–2106. https://doi.org/10.1172/JCI123955
doi: 10.1172/JCI123955
pubmed: 30860984
pmcid: 6486333
Sanchez-Correa B, Morgado S, Gayoso I, Bergua JM, Casado JG, Arcos MJ, Bengochea ML, Duran E, Solana R, Tarazona R (2011) Human NK cells in acute myeloid leukaemia patients: analysis of NK cell-activating receptors and their ligands. Cancer Immunol Immunother 60(8):1195–1205. https://doi.org/10.1007/s00262-011-1050-2
doi: 10.1007/s00262-011-1050-2
pubmed: 21644031
Groh V, Wu J, Yee C, Spies T (2002) Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419(6908):734–738. https://doi.org/10.1038/nature01112
doi: 10.1038/nature01112
pubmed: 12384702
Mamessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquemier J, Castellano R, Goncalves A, Andre P, Romagne F, Thibault G, Viens P, Birnbaum D, Bertucci F, Moretta A, Olive D (2011) Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. J Clin Invest 121(9):3609–3622. https://doi.org/10.1172/JCI45816
doi: 10.1172/JCI45816
pubmed: 21841316
pmcid: 3171102
Peng YP, Zhang JJ, Liang WB, Tu M, Lu ZP, Wei JS, Jiang KR, Gao WT, Wu JL, Xu ZK, Miao Y, Zhu Y (2014) Elevation of MMP-9 and IDO induced by pancreatic cancer cells mediates natural killer cell dysfunction. BMC Cancer 14:738. https://doi.org/10.1186/1471-2407-14-738
doi: 10.1186/1471-2407-14-738
pubmed: 25274283
pmcid: 4287420
da Silva IP, Gallois A, Jimenez-Baranda S, Khan S, Anderson AC, Kuchroo VK, Osman I, Bhardwaj N (2014) Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade. Cancer Immunol Res 2(5):410–422. https://doi.org/10.1158/2326-6066.CIR-13-0171
doi: 10.1158/2326-6066.CIR-13-0171
pubmed: 24795354
pmcid: 4046278
Jovic V, Konjevic G, Radulovic S, Jelic S, Spuzic I (2001) Impaired perforin-dependent NK cell cytotoxicity and proliferative activity of peripheral blood T cells is associated with metastatic melanoma. Tumori 87(5):324–329
doi: 10.1177/030089160108700509
pubmed: 11765182
Kobayashi T, Lam PY, Jiang H, Bednarska K, Gloury R, Murigneux V, Tay J, Jacquelot N, Li R, Tuong ZK, Leggatt GR, Gandhi MK, Hill MM, Belz GT, Ngo S, Kallies A, Mattarollo SR (2020) Increased lipid metabolism impairs NK cell function and mediates adaptation to the lymphoma environment. Blood 136(26):3004–3017. https://doi.org/10.1182/blood.2020005602
doi: 10.1182/blood.2020005602
pubmed: 32818230
Konjevic G, Jurisic V, Spuzic I (2001) Association of NK cell dysfunction with changes in LDH characteristics of peripheral blood lymphocytes (PBL) in breast cancer patients. Breast Cancer Res Treat 66(3):255–263. https://doi.org/10.1023/a:1010602822483
doi: 10.1023/a:1010602822483
pubmed: 11510697
Jurisic V, Srdic T, Konjevic G, Markovic O, Colovic M (2007) Clinical stage-depending decrease of NK cell activity in multiple myeloma patients. Med Oncol 24(3):312–317. https://doi.org/10.1007/s12032-007-0007-y
doi: 10.1007/s12032-007-0007-y
pubmed: 17873307
Esen F, Deniz G, Aktas EC (2021) PD-1, CTLA-4, LAG-3, and TIGIT: The roles of immune checkpoint receptors on the regulation of human NK cell phenotype and functions. Immunol Lett 240:15–23. https://doi.org/10.1016/j.imlet.2021.09.009
doi: 10.1016/j.imlet.2021.09.009
pubmed: 34599946
Quatrini L, Mariotti FR, Munari E, Tumino N, Vacca P, Moretta L (2020) The Immune checkpoint PD-1 in natural killer cells: expression function and targeting in tumour immunotherapy. Cancers (Basel) 12(11):3285
doi: 10.3390/cancers12113285
pubmed: 33172030
Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, Iyer AK (2017) PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol 8:561. https://doi.org/10.3389/fphar.2017.00561
doi: 10.3389/fphar.2017.00561
pubmed: 28878676
pmcid: 5572324
Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12(4):252–264. https://doi.org/10.1038/nrc3239
doi: 10.1038/nrc3239
pubmed: 22437870
pmcid: 4856023
Warren RP, Lum LG, Storb R (1985) Is the leukocyte group-5a antigen associated with reduced NK cell function? Tissue Antigens 25(2):107–110. https://doi.org/10.1111/j.1399-0039.1985.tb00423.x
doi: 10.1111/j.1399-0039.1985.tb00423.x
pubmed: 3922087
Tallerico R, Todaro M, Di Franco S, Maccalli C, Garofalo C, Sottile R, Palmieri C, Tirinato L, Pangigadde PN, La Rocca R, Mandelboim O, Stassi G, Di Fabrizio E, Parmiani G, Moretta A, Dieli F, Karre K, Carbone E (2013) Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules. J Immunol 190(5):2381–2390. https://doi.org/10.4049/jimmunol.1201542
doi: 10.4049/jimmunol.1201542
pubmed: 23345327